Jul 14 2022
The number of patients with nonalcoholic fatty liver disease (NAFLD) is increasing worldwide. Various factors including obesity, diabetes, abnormal hormone secretion and genetic predisposition are related to it etiology, therefore, it is essential to elucidate the pathological conditions and develop effective treatment methods. The research group led by Professor KAMIMURA Kenya (Department of General Medicine, Niigata University School of Medicine/Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University), OWAKI Takashi (graduate student) and Professor TERAI Shuji in the same division elucidated that the serotonin1 receptors2 in the liver are involved in the pathological progression of NAFLD and that administering the receptor antagonist3 can be an effective new treatment method.
Journal:?Disease Models & Mechanisms
Title:?The liver–gut peripheral neural axis and nonalcoholic fatty liver disease pathologies?via?hepatic serotonin receptor 2A
Authors: Takashi Owaki, Kenya Kamimura, Masayoshi Ko, Itsuo Nagayama, Takuro Nagoya, Osamu Shibata, Chiyumi Oda, Shinichi Morita, Atsushi Kimura, Takeki Sato, Toru Setsu, Akira Sakamaki, Hiroteru Kamimura, Takeshi Yokoo, and Shuji Terai
DOI: 10.1242/dmm.049612
The article was released in?EurekAlert, the online publication of the American Association for the Advancement of Science.
Low Intake of Fruits and Vegetables Is Associated with Higher 10-Year Mortality Risk in Patients with Chronic Kidney Disease on Hemodialysis
New Drug Candidate for Spinocerebellar Ataxia ~Clinical Trial Results of L-Arginine for Spinocerebellar Ataxia Type 6~
CRISPR/CasRx suppresses KRAS-induced brain arteriovenous malformation developed in postnatal brain endothelial cells in mice